Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease
- PMID: 19903096
- DOI: 10.3109/14653240903121260
Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease
Abstract
Background aims: Because of their capacity to modulate the immune response and promote tissue repair, mesenchymal stromal cells (MSC) represent a potential novel treatment for autoimmune/inflammatory diseases, including Crohn's disease (CD). The aim of the study was in vitro characterization of MSC from active CD patients for future clinical application.
Methods: MSC from the bone marrow (BM) of seven CD patients (median age 32 years) were expanded ex vivo in the presence of 5% platelet lysate; cells were investigated for clonogenic efficiency, proliferative capacity, morphology, immunophenotype, differentiation potential, genetic stability and ability to suppress in vitro proliferation of both autologous and allogeneic lymphocytes to polyclonal mitogens. Results were compared with those of BM MSC of four healthy donors (HD).
Results: MSC were successfully expanded from all patients. Colony-forming unit-fibroblast (CFU-F) frequency and proliferative capacity were comparable in CD and HD MSC. CD MSC showed typical spindle-shaped morphology and differentiated into osteoblasts, adipocytes and chondrocytes. Surface immunologic markers did not differ between CD and HD MSC, with the only exception of sizeable levels of HLA-DR at early culture passages [12-84% at passage (P)1] in the former. CD MSC ceased their growth at variable passages (from P8 to P25) and entered senescence without any change in morphology/proliferation rate. Array-comparative genomic hybridization demonstrated that CD MSC do not show imbalanced chromosomal rearrangements. Both CD and HD MSC inhibited in vitro proliferation of lymphocytes to mitogens.
Conclusions: CD MSC show biologic characteristics similar to HD MSC and can be considered for anti-inflammatory and reparative cell therapy approaches in patients with refractory disease.
Similar articles
-
Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.Rheumatology (Oxford). 2007 Mar;46(3):403-8. doi: 10.1093/rheumatology/kel267. Epub 2006 Aug 18. Rheumatology (Oxford). 2007. PMID: 16920750
-
Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.Gut. 2010 Dec;59(12):1662-9. doi: 10.1136/gut.2010.215152. Epub 2010 Oct 4. Gut. 2010. PMID: 20921206 Clinical Trial.
-
Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations.J Cell Physiol. 2010 May;223(2):530-40. doi: 10.1002/jcp.22081. J Cell Physiol. 2010. PMID: 20162565
-
Human bone marrow mesenchymal stem cells in vivo.Rheumatology (Oxford). 2008 Feb;47(2):126-31. doi: 10.1093/rheumatology/kem206. Epub 2007 Nov 6. Rheumatology (Oxford). 2008. PMID: 17986482 Review.
-
Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies?Exp Gerontol. 2008 Nov;43(11):1018-23. doi: 10.1016/j.exger.2008.07.004. Epub 2008 Jul 24. Exp Gerontol. 2008. PMID: 18694815 Review.
Cited by
-
Mesenchymal Stem Cell Senescence and Rejuvenation: Current Status and Challenges.Front Cell Dev Biol. 2020 Jun 3;8:364. doi: 10.3389/fcell.2020.00364. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32582691 Free PMC article. Review.
-
Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients.ERJ Open Res. 2016 Jun 28;2(2):00045-2015. doi: 10.1183/23120541.00045-2015. eCollection 2016 Apr. ERJ Open Res. 2016. PMID: 27730190 Free PMC article.
-
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy.Curr Pharm Des. 2013;19(13):2459-73. doi: 10.2174/1381612811319130015. Curr Pharm Des. 2013. PMID: 23278600 Free PMC article. Review.
-
Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw.Stem Cell Res Ther. 2016 Aug 17;7(1):119. doi: 10.1186/s13287-016-0367-3. Stem Cell Res Ther. 2016. PMID: 27530108 Free PMC article.
-
Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease.World J Gastroenterol. 2015 Apr 28;21(16):4779-87. doi: 10.3748/wjg.v21.i16.4779. World J Gastroenterol. 2015. PMID: 25944991 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials